New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions

Pharmaceutical Research and Manufacturers of America

18 January 2019 - A new whitepaper authored by Bruce Pyenson and colleagues from Milliman explains why ICER potential budget impact analyses are not very useful for private payers’ budget decisions.

The whitepaper’s authors identify several weaknesses in ICER’s budget impact analysis, which they believe limits the usefulness of this approach for private payers.

Read PhRMA blog

Michael Wonder

Posted by:

Michael Wonder